Compare Vanguard Value Index Fund ETF (VTV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Value Index Fund ETF trades at $227.5, while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VTV | WGS | |
|---|---|---|
52-Week High | $225.35 | $167.51 |
52-Week Low | $179.43 | $34.51 |
Market Cap | — | $2.44B |
Sector | — | Technology |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Value ETF (VTV) trades at $226.29, up 0.56% today, with a bullish technical signal from moving averages. The ETF focuses on large-cap U.S. value stocks and is benefiting from a rotation into value strategies in 2026, with one Vanguard deep-value fund reportedly up 22% this year. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduce holdings.
The outlook for VTV is positive amid the shift toward value investing, though the RSI-6 at 90.75 indicates potential overbought conditions. Risks include market volatility and sector concentration, but its diversified value approach offers stability if growth stocks underperform. Analyst sentiment remains constructive on value ETFs for income and defensive positioning.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
